Merck & Co., Inc. (MRK)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$5,398.0M
Cash & Equivalents
$3,918.0M
Quarterly Burn Rate
$296,972M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (39 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
ASPARAGINASE
ELSPAR |
APPROVED | — |
|
CHLOROTHIAZIDE, RESERPINE
DIUPRES-250 |
NDA | — |
|
BENZTROPINE MESYLATE
COGENTIN |
NDA | — |
|
ANILERIDINE HYDROCHLORIDE
LERITINE |
NDA | — |
|
DILTIAZEM MALATE
TIAMATE |
NDA | — |
|
CORTISONE ACETATE
CORTONE |
NDA | — |
|
DIFLUNISAL
DOLOBID |
NDA | — |
|
ANILERIDINE PHOSPHATE
LERITINE |
NDA | — |
|
MANNITOL
MANNITOL 25% |
NDA | — |
|
NORFLOXACIN
NOROXIN |
NDA | — |
|
HYDROXOCOBALAMIN
ALPHAREDISOL |
NDA | — |
|
CYPROHEPTADINE HYDROCHLORIDE
PERIACTIN |
NDA | — |
|
ISOFLUROPHATE
FLOROPRYL |
NDA | — |
|
AMILORIDE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE
MODURETIC 5-50 |
NDA | — |
|
CASPOFUNGIN ACETATE
CANCIDAS |
NDA | — |
|
DEXAMETHASONE SODIUM PHOSPHATE, NEOMYCIN SULFATE
NEODECADRON |
NDA | — |
|
NEOMYCIN SULFATE, PREDNISOLONE SODIUM PHOSPHATE
NEO-HYDELTRASOL |
NDA | — |
|
METARAMINOL BITARTRATE
ARAMINE |
NDA | — |
|
SULINDAC
CLINORIL |
NDA | — |
|
HYDROCHLOROTHIAZIDE, TIMOLOL MALEATE
TIMOLIDE 10-25 |
NDA | — |
|
CILASTATIN SODIUM, IMIPENEM
PRIMAXIN |
NDA | — |
|
AMINOHIPPURATE SODIUM
AMINOHIPPURATE SODIUM |
NDA | — |
|
PROBENECID
BENEMID |
NDA | — |
|
CHLOROTHIAZIDE, METHYLDOPA
ALDOCLOR-150 |
NDA | — |
|
DEXAMETHASONE SODIUM PHOSPHATE, LIDOCAINE HYDROCHLORIDE
DECADRON W/ XYLOCAINE |
NDA | — |
|
HYDROCHLOROTHIAZIDE, LISINOPRIL
PRINZIDE |
NDA | — |
|
ROFECOXIB
VIOXX |
NDA | — |
|
METHYLDOPA
ALDOMET |
NDA | — |
|
HEXYLCAINE HYDROCHLORIDE
CYCLAINE |
NDA | — |
|
CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER |
NDA | — |
|
HYDROCHLOROTHIAZIDE, RESERPINE
HYDROPRES 50 |
NDA | Acute Bacterial Gastroenteritis, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Advanced Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Solid Tumors, Anovulation, Asthma, Atherosclerosis, Bacteremia, Bacterial Infection, Bacterial Infections, Bladder Pain Syndrome, Bloodloss, Bowel Dysfunction, BRAF V600E-mutant Metastatic Colorectal Cancer, Cancer, Candidiasis, Vulvovaginal, Carcinoma, Squamous Cell, Cervical Cancer, Cholangiocarcinoma, Chronic Kidney Disease, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disorder, Clear Cell Renal Cell Carcinoma (ccRCC), Clostridium Difficile, Clostridium Difficile Infection, Complicated Skin and Skin Structure Infections, COPD, Coronary Disease, Coronary Heart Disease, Coronavirus Infection, COVID-19, Critically Ill, Crohn's Disease, Diarrhea, Diffuse Large B-Cell Lymphoma, Endocarditis, Bacterial, Endometrial Cancer, ER-negative Breast Cancer, ER-positive Breast Cancer, Estrogen Receptor Positive |
|
METHYLDOPATE HYDROCHLORIDE
ALDOMET |
NDA | — |
|
DEXAMETHASONE ACETATE
DECADRON-LA |
NDA | — |
|
DEMECARIUM BROMIDE
HUMORSOL |
NDA | — |
|
HYDROCORTISONE SODIUM PHOSPHATE
HYDROCORTONE |
NDA | — |
|
LOVASTATIN
MEVACOR |
NDA | — |
|
HYDROCHLOROTHIAZIDE, METHYLDOPA
ALDORIL D30 |
NDA | — |
|
COLCHICINE, PROBENECID
COLBENEMID |
NDA | — |
|
PREDNISOLONE TEBUTATE
HYDELTRA-TBA |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.